Abbott Launches Innovative XIENCE Skypoint Stent in India

Abbott has introduced the XIENCE Skypoint, a drug eluting stent designed to treat complex heart blockages in India. The device is noted for its flexibility and precision, aiming to support doctors in managing cardiovascular disease, a leading cause of mortality linked to lifestyle risks in the country.

Abbott, a global healthcare leader, announced on Tuesday the release of its innovative drug eluting stent, XIENCE Skypoint, in India. This cutting-edge device is crafted to address complex heart blockages with greater precision and flexibility.

The company highlights the new stent's ability to navigate through the heart's arteries, including larger vessels, providing a significant advancement for cardiovascular treatment. This development is particularly pertinent given the rising incidence of severe blockages attributed to hypertension, diabetes, and other lifestyle factors that are prevalent in India.

Tushar Sharma, general manager of Abbott's vascular division in India and South Asia, emphasized the stent's value in supporting doctors treating cardiovascular disease, asserting the company's commitment to enhancing patient outcomes through advanced medical technologies.

(With inputs from agencies.)